Acrux CEO Michael Kotsanis Announces Retirement

Acrux Limited ( (AU:ACR) ) has issued an update.

Michael Kotsanis, the CEO of Acrux Limited, has announced his retirement after a significant tenure, during which he successfully developed the company’s generic drug strategy. This strategy has led to the generation of a diverse product suite, and recent capital raising efforts aim to expand the product portfolio with further FDA filings. The Board has initiated a search for a new CEO to lead the next phase of Acrux’s development and growth.

More about Acrux Limited

Acrux is a specialty pharmaceutical company with 25 years of experience in developing and commercializing topically applied pharmaceutical products. The company has successfully marketed various products worldwide, with a primary focus on the United States, and is engaged in formulating and developing a range of topical generic products.

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.81M

For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.